- Medacta USA Spine Division nearly doubles revenue versus Q1 2016 -
- Division releases additional configuration for the MectaLIF Anterior Lumbar Stand Alone Device product suite -
CASTEL SAN PIETRO, Switzerland--(BUSINESS WIRE)--Medacta International, the privately held family-owned global leader in the design of innovative joint replacement and spine surgery products, today announced that the company’s USA Spine Division delivered strong growth in the first quarter of 2017 and introduced key new products that will continue to expand Medacta’s offerings in the spine field.
Coming off the appointment of a new medical director and important product launches, the Medacta USA Spine Division nearly doubled its sales revenue from the comparable quarter last year. The division released three new products in 2016, including the MySpine Low Profile Guide, receiving numerous accolades for their clinical success and high praise from the surgeons who use them.
Francesco Siccardi, Executive Vice President of Medacta International, commented: “Medacta always strives to produce exceptional products that are built around surgeon feedback and provide the best possible patient experience. The success of this team is a proof point for the Medacta way: a maintained focus on surgeon education and smart design.”
Medacta’s latest innovation, the MectaLIF Anterior Hybrid Interbody Fusion Device, was cleared by the U.S. Food and Drug Administration (FDA) in February 2017 and will be an addition to the MectaLIF Cage product suite. The MectaLIF System aims to provide enhanced in situ stability, restoration of the native disc space height and lordosis, and long-term maintenance of the spinal balance. With the addition of the new hybrid configuration, the MectaLIF product line will now offer four different configurations (hybrid, anterior flush, anterior long, and anterior L5-S1), three footprints, two materials (PEEK or Titanium-coated PEEK (TiPEEK)), and hyperlordotic 20-degree cage options, allowing surgeons to target any patient-specific abnormalities they may encounter.
“The addition of the hybrid makes MectaLIF even more versatile,” said Dr. S. Raymond Golish, Medical Director of Medacta’s Spine Division. “We offer surgeons a wide variety of implants tailored to surgeon technique and patient anatomy to optimize outcomes.”
The addition of the MectaLIF hybrid configuration will enable personalized care for patients where additional stability is required and low profile construct is necessary to deal with difficult, tilted anatomies, by offering a flush caudal and long cranial profile in conjunction with low angle, diverging screws. In addition to the new configuration, the FDA cleared the hyper lordotic option and a 40x30mm footprint to further supplement the MectaLIF product suite and offer a wider array of options to patients.
About Medacta
Medacta® International is a world leading manufacturer of orthopedic implants, neurosurgical systems, and instrumentation. Medacta’s revolutionary approach and responsible innovation have resulted in standard of care breakthroughs in hip replacement with the AMIS® system and total knee replacement with MyKnee® patient matched technology. Over the last 10 years, Medacta has grown dramatically by taking a different approach and placing value on all aspects of the care experience from design to training to sustainability. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 30 countries. To learn more about Medacta International, please visit www.medacta.com or follow @Medacta on Twitter.
